Clinical Trial

Seizure Treatment in Glioma

Study acronym: STING
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Currently, treatment with a specific anti-epileptic drug mainly depends on the physicians' preference, as there are no studies supporting the use of one specific anticonvulsant in glioma patients. The overall aim of this randomized controlled trial is to directly compare the effectiveness of treatment with levetiracetam or valproic acid in glioma patients with a first seizure.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-02-07; most recent amendment 2025-01-31.
Status change: Not Yet Recruiting → Recruiting 2018-03-05
Trial Details
NCT Number NCT03048084
Lead Sponsor Leiden University Medical Center
Collaborators: Medical Center Haaglanden, Erasmus Medical Center, Amsterdam UMC, location VUmc
Conditions Glioma
Enrollment 120 participants
Start Date 2018-02-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-04